



**FOR IMMEDIATE RELEASE**

**Media Contact**

Rx Communications Group, LLC  
Eric Goldman  
Vice President, Public Relations  
917-322-2563  
egoldman@rxir.com

**Omthera Pharmaceuticals, Inc. to Present at the  
29<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

**Bedminster, NJ, January 5, 2011** – Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that Jerry Wisler, President and Chief Executive Officer, will present at the 29<sup>th</sup> Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA on Thursday, January 13, 2011 at 10:30am PT.

**About Omthera Pharmaceuticals, Inc.**

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. The lead product candidate is Epanova, an Omega 3 fatty acid compound preparing to enter Phase III clinical development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides ( $\geq 500$  mg/dL). Future planned clinical trials for Epanova include patients with high triglycerides ( $\geq 200$  mg/dL and  $\leq 500$  mg/dL) currently on statin therapy. Omthera holds worldwide rights to Epanova. For more information, please visit [www.omthera.com](http://www.omthera.com).

###